EMEA-003134-PIP01-21
Key facts
Active substance |
Nifurtimox
|
Therapeutic area |
Infectious diseases
|
Decision number |
P/0081/2022
|
PIP number |
EMEA-003134-PIP01-21
|
Pharmaceutical form(s) |
Tablet
|
Condition(s) / indication(s) |
Treatment of Chagas disease
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Bayer AG, Leverkusen
E-mail: clinical-trials-contact@bayer.com |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
Compliance procedure number |
EMEA-C-003134-PIP01-21
|
Compliance opinion date |
09/09/2022
|
Compliance outcome |
positive
|